Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
